Patents Assigned to Heidelberg Pharma GmbH
-
Patent number: 10842882Abstract: The invention relates to conjugates comprising amatoxins and antibodies, in particular amatoxins linked to antibodies comprising specific cysteine residues.Type: GrantFiled: March 7, 2016Date of Patent: November 24, 2020Assignee: Heidelberg Pharma GmbHInventors: Jan Anderl, Torsten Hechler, Christoph Müller, Andreas Pahl
-
Publication number: 20180185509Abstract: The present disclosure relates to tumour therapy. In one aspect, the present disclosure relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.Type: ApplicationFiled: October 9, 2017Publication date: July 5, 2018Applicant: Heidelberg Pharma GmbHInventors: Werner Simon, Christian Lutz, Christoph Müller, Jan Anderl
-
Patent number: 9982018Abstract: The invention relates to tumor therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer and other disorders and diseases. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.Type: GrantFiled: March 10, 2014Date of Patent: May 29, 2018Assignee: Heidelberg Pharma GmbHInventors: Christoph Müller, Jan Anderl, Werner Simon, Christian Lutz, Torsten Hechler
-
Publication number: 20180043033Abstract: The invention relates to conjugates comprising amatoxins and antibodies, in particular amatoxins linked to antibodies comprising specific cysteine residues.Type: ApplicationFiled: March 7, 2016Publication date: February 15, 2018Applicant: HEIDELBERG PHARMA GMBHInventors: Jan ANDERL, Torsten HECHLER, Christoph MÜLLER, Andreas PAHL
-
Patent number: 9676702Abstract: The invention relates to novel methods for synthesizing a synthon for ?,?-dihydroxyisoleucine 1 (CAS No. 55399-94-5] as building block for the synthesis of amatoxins, and for novel methods for synthesizing amatoxins using such building block.Type: GrantFiled: July 12, 2013Date of Patent: June 13, 2017Assignee: Heidelberg Pharma GmbHInventors: Christian Lutz, Christoph Mueller, Werner Simon
-
Patent number: 9630907Abstract: The invention relates to novel methods for synthesizing a synthon for ?,?-dihydroxyisoleucine 1 (CAS No. 55399-94-5] as building block for the synthesis of amatoxins, and for novel methods for synthesizing amatoxins using such building block.Type: GrantFiled: July 12, 2013Date of Patent: April 25, 2017Assignee: Heidelberg Pharma GmbHInventors: Christian Lutz, Christoph Mueller, Werner Simon
-
Publication number: 20160002298Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer and other disorders and diseases. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.Type: ApplicationFiled: March 10, 2014Publication date: January 7, 2016Applicant: HEIDELBERG PHARMA GMBHInventors: Christoph MÜLLER, Jan ANDERL, Werner SIMON, Christian LUTZ, Torsten HECHLER
-
Publication number: 20150210628Abstract: The invention relates to novel methods for synthesizing a synthon for ?,?-dihydroxyisoleucine 1 (CAS No. 55399-94-5] as building block for the synthesis of amatoxins, and for novel methods for synthesizing amatoxins using such building block.Type: ApplicationFiled: July 12, 2013Publication date: July 30, 2015Applicant: Heidelberg Pharma GmbHInventors: Christian Lutz, Christoph Mueller, Werner Simon
-
Publication number: 20140294865Abstract: The invention relates to tumor therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.Type: ApplicationFiled: March 9, 2012Publication date: October 2, 2014Applicant: HEIDELBERG PHARMA GMBHInventors: Werner Simon, Christian Lutz, Christoph Muller, Jan Anderl
-
Publication number: 20130259880Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by a linker comprising a urea moiety, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.Type: ApplicationFiled: September 29, 2011Publication date: October 3, 2013Applicant: HEIDELBERG PHARMA GMBHInventors: Jan Anderl, Werner Simon, Christoph Mueller
-
Patent number: 7378401Abstract: The present invention is directed to the systemic administration of Fosfluridine Tidoxil, (5-fluorouridine)-5?-phosphoric acid (3-dodecylmercapto-2-decyloxy)propylester or a salt thereof, for the treatment of intraepithelial proliferative diseases such as actinic keratosis. The Fosfluridine Tidoxil can be systemically administered alone or in combination with topical treatment agents.Type: GrantFiled: July 14, 2006Date of Patent: May 27, 2008Assignee: Heidelberg Pharma GmbHInventors: Erwin Boehm, Michael Kulke, Eggert Stockfleth
-
Publication number: 20080014258Abstract: The present invention is directed to the systemic administration of Fosfluridine Tidoxil, (5-fluorouridine)-5?-phosphoric acid (3-dodecylmercapto-2-decyloxy)propylester or a salt thereof, for the treatment of intraepithelial proliferative diseases such as actinic keratosis. The Fosfluridine Tidoxil can be systemically administered alone or in combination with topical treatment agents.Type: ApplicationFiled: July 14, 2006Publication date: January 17, 2008Applicant: HEIDELBERG PHARMA GMBHInventors: Erwin Boehm, Michael Kulke, Eggert Stockfleth
